#540 Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)

Annika Auranen ,Vladyslav Sukhin,Shadi Stevens ,Christine Dabrowski ,Dirk Olaf Bauerschlag ,Graziana Ronzino ,Roy I Lalisang ,Robert L Coleman ,Lisa M Landrum ,Amy E Armstrong ,Joseph Buscema ,Lucy Gilbert ,Lyndsay Willmott ,David Bender ,Destin Black ,Sudarshan Sharma ,Matthew A Powell ,Nicole S Nevadunsky ,Mansoor Raza Mirza ,Evelyn Fleming

doi:10.1136/ijgc-2023-esgo.16

#540 Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)

Annika Auranen , Vladyslav Sukhin + Show 18 more

Open Access

https://doi.org/10.1136/ijgc-2023-esgo.16

Copy DOI

Journal: International Journal of Gynecologic Cancer	Publication Date: Sep 1, 2023
Citations: 1

#Treatment-emergent Adverse Events #Recurrent Endometrial Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Introduction/BackgroundIn the phase 3 RUBY trial (NCT03981796) in patients with primary advanced or recurrent endometrial cancer (pA/rEC) dostarlimab+carboplatin/paclitaxel significantly improved PFS versus carboplatin/paclitaxel alone in the mismatch repair deficient/microsatellite instability-high...

Full Text